Engineered E. coli colonies could be trump cards in the war against drug resistance
Stephanie Sutton |
Antibiotic resistance has been described as one of the most significant threats facing patient safety. Could E. coli lend a helping hand in the fight? Yes, according to a research team at the University at Buffalo led by Blaine Pfeifer, associate professor of chemical and biological engineering. The team has engineered E. coli to synthesize 42 new forms of the antibiotic erythromycin – three of which have been shown to be effective against bacteria resistant to the version of erythromycin currently used in clinics. And the E. coli factory could be used to produce even more variations. We spoke with Pfeifer to find out more.
How did the work begin?
I was interested in making natural products more accessible by developing alternative production routes. In this case, we were able to produce the antibiotic erythromycin through a heterologous host system and then use the engineering tools of the new platform to produce analogs of the original compound. Production through E. coli provides a maximum operating space that few other production routes can offer.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.